Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (Q85678153)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 2014

Language	Label	Description	Also known as
English	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial	scientific article published on 01 October 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Frederick J Raal

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Narimon Honarpour

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dirk J Blom

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

G Kees Hovingh

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Feng Xu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Scott M Wasserman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Evan A Stein

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

TESLA Investigators

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

0 references

publication date

1 October 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

385

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

341-350

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

9965

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the use of LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein(a) in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61374-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85678153&oldid=2041797103"